We aim to develop novel imaging biomarkers in the field of Positron Emission Tomography/Computed Tomography (PET/CT) and to generate empirical evidence for the purpose of analytical and clinical validation of the imaging biomarkers as indicators of prognosis and treatment efficacy in metastatic prostate cancer (PCa). Such validated imaging biomarkers would not only transform future clinical care but would also accelerate the development of therapies for PCa. The work will take the form of multidisciplinary collaboration between researchers from the fields of nuclear medicine, urology and mathematics, and the clinical validation will be performed as retrospective and prospective multicentric studies. The specific objectives of this project are:

  • To develop new imaging biomarkers for PET/CT images from metastatic PCa patients
  • To analytically validate the PET/CT imaging biomarkers
  • To clinically validate the PETC/CT imaging biomarkers in a predefined clinical context


  • RECOMIA - a cloud-based platform for artificial intelligence research in nuclear medicine and radiology. Trägårdh E, Borrelli P, Kaboteh R, Gillberg T, Ulén J, Enqvist O, Edenbrandt L. EJNMMI Phys. 2020:4;7:51.
  • Deep learning‐based quantification of PET/CT prostate gland uptake: association with overall survival. Polymeri E, Sadik M, Kaboteh R, Borrelli P, Enqvist O, Ulén J, Ohlsson M, Trägårdh E, Poulsen MH, Simonsen JA, Hoilund-Carlsen PF, Johnsson ÅA, Edenbrandt L. Clin Physiol Funct Imaging. 2020;40:106-113.
  • Deep learning for segmentation of 49 selected bones in CT scans: First step in automated PET/CT-based 3D quantification of skeletal metastases. Lindgren Belal S, Sadik M, Kaboteh R, Enqvist O, Ulén J, Poulsen MH, Simonsen J, Høilund-Carlsen PF, Edenbrandt L, Trägårdh E. Eur J Radiol 2019;113:89-95.
  • Artificial intelligence-based versus manual assessment of prostate cancer in the prostate gland: a method comparison study. Mortensen MA, Borrelli P, Poulsen MH, Gerke O, Enqvist O, Ulén J, Trägårdh E, Constantinescu C, Edenbrandt L, Lund L, Høilund-Carlsen PF. Clin Physiol Funct Imaging. 2019:39;399-406.
  • The use of a proposed updated EARL harmonization of 18F-FDG PET-CT in patients with lymphoma yields significant differences in Deauville score compared with current EARL recommendations. Ly J, Minarik D, Edenbrandt L, Wollmer P, Trägårdh E. EJNMMI Res. 2019;9:65.
  • Automated quantification of reference levels in liver and mediastinal blood pool for the Deauville therapy response classification using FDG‐PET/CT in Hodgkin and non‐Hodgkin lymphomas. Sadik M, Lind E, Polymeri E, Enqvist O, Ulen J, Trägårdh E. Clin Physiol Funct Imaging. 2019;39:78-84.
  • 3D skeletal uptake of 18F sodium fluoride in PET/CT images is associated with overall survival in patients with prostate cancer. Lindgren Belal S, Sadik M, Kaboteh R, Hasani N, Enqvist O, Svärm L, Kahl F, Simonsen J, Poulsen MH, Ohlsson M, Høilund-Carlsen PF, Edenbrandt L, Trägårdh E. EJNMMI Res 2017;7:1.